Population pharmacokinetics/pharmacodynamics of anesthetics

AAPS Journal

Volumn 7, Issue 2, 2005, Pages

  Olofsen, Erik ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anesthetics; NONMEM; PK PD modeling

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANESTHETIC AGENT; DESFLURANE; HYPNOTIC AGENT; MIDAZOLAM; MORPHINE; MORPHINE 6 GLUCURONIDE; OPIATE; PROPOFOL; REMIFENTANIL; ROCURONIUM; SEVOFLURANE; THIOPENTAL;

AGE; ANALGESIA; ANALYSIS OF COVARIANCE; ANESTHESIOLOGY; BAYES THEOREM; BODY WEIGHT; CLINICAL TRIAL; CONSCIOUSNESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG POTENTIATION; GENDER; HUMAN; HYPOXIA; INFORMATION PROCESSING; NOCICEPTIVE STIMULATION; PHARMACODYNAMICS; POPULATION MODEL; RESPIRATION DEPRESSION; REVIEW; SEDATION; STATISTICAL ANALYSIS;

ANESTHETICS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 30544450901     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070239     Document Type: Review

References (63)

1. NONMEM Project Group. NONMEM User's Guide. San Francisco, CA: University of California; 1999.
2. Minto CF, Schnider TW. Expanding clinical applications of population pharmacodynamic modeling. Br J Clin Pharmacol. 1998;46:321-333.
3. Wright PMC. Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics. Br J Anaesth. 1998;80:488-501.
4. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet. 1986;11:387-401.
5. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology. 1987;66:3-12.
6. Grevel J, Whiting B. The relevance of pharmacokinetics to optimal intravenous anesthesia. Anesthesiology. 1987;66:1-2.
7. Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology. 1994;80:104-122.
8. Fisher DM. Propofol in pediatrics. Lessons in pharmacokinetic modeling. Anesthesiology. 1994;80:2-5.
9. Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92:727-738.
10. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998;88:1170-1182.
11. Hull CJ. How far can we go with compartmental models? Anesthesiology. 1990;72:399-402.
12. Boer F. Drug handling by the lungs. Br J Anaesth. 2003;91:50-60.
13. Krejcie TC, Henthorn TK, Shanks CA, Avram MJ. A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs. J Pharm Exp Ther. 1994;269:609-616.
14. Kuipers JA, Boer F, Olofsen E, Bovill JG, Burm AGL. Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients - the influence of cardiac output. Anesthesiology. 2001;94:47-55.
15. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tabocurarine. Clin Pharmacol Ther. 1979;25:358-371.
16. Stanski DR, Maitre PO. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. Anesthesiology. 1990;72:412-422.
17. Somma J, Donner A, Zomorodi K, et al. Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery. Anesthesiology. 1998;89:1430-1443.
18. Fábregas N, Rapado J, Gambús PL, et al. Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. Anesthesiology. 2002;97:1378-1386.
19. Knibbe CAJ, Zuideveld KP, DeJongh J, Kuks PFM, Aarts LPHJ, Danhof M. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther. 2002;72:670-684.
20. Doufas AG, Baklishandeh M, Bjorksten AR, Shafer SL, Sessler DI. Induction speed is not a determinant of propofol pharmacodynamics. Anesthesiology. 2004;101:1112-1121.
21. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86:10-23.
22. Anderson BJ, Holford NHG, Woollard GA, Kanagasundaram S, Mahadevan M. Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology. 1999;90:411-421.
23. Rehberg B, Bouillon T, Grünewald M, et al. Comparison of the concentration-dependent effect of sevoflurane on the spinal H-reflex and the EEG in humans. Acta Anaesthesiol Scand. 2004;48:569-576.
24. Johansen JW, Sebel PS. Development and clinical application of electroencephalographic bispectrum monitoring. Anesthesiology. 2000;93:1336-1344.
25. Röpcke H, Rehberg B, Koenen-Bergmann M, Bouillon T, Bruhn J, Hoeft A. Surgical stimulation shifts EEG concentration-response relationship of desflurane. Anesthesiology. 2001;94:390-399.
26. Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93:1245-1254.
27. Luginbühl M, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Comparison of five experimental pain tests to measure analgesic effects of alfentanil. Anesthesiology. 2001;95:22-29.
28. Olofsen E, Romberg R, Bijl H, et al. Alfentanil and placebo analgesia: no sex differences detected in models of experimental pain. Anesthesiology. 2005;103:130-139.
29. Romberg RR, Olofsen E, Bijl H, et al. Polymorphism of μ-opioid receptor gene (OPRM1:c. 118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102:522-530.
30. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology. 2003;99:788-798.
31. Bouillon T, Bruhn J, Radu-Radulescu L, Andresen C, Cohane C, Shafer SL. A model of the ventilatory-depressant potency of remifentanil in the non-steady state. Anesthesiology. 2003;99:779-787.
32. Dahan A, Romberg R, Teppema L, Sarton E, Bijl H, Olofsen E. Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. Anesthesiology. 2004;101:1201-1209.
33. Olofsen E, Sleigh JW, Dahan A. The influence of remifentanil on the dynamic relationship between sevoflurane and surrogate anesthetic effect measures derived from the EEG. Anesthesiology. 2002;96:555-564.
34. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. Response surface model for anesthetic drug interactions. Anesthesiology. 2000;92:1603-1616.
35. Bouillon TW, Bruhn J, Radulescu L, et al. Pharmacodynamic interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. Anesthesiology. 2004;100:1353-1372.
36. Dahan A, Nieuwenhuijs D, Olofsen E, Sarton E, Romberg R, Teppema L. Response surface modeling of alfentanil-sevoflurane interaction on cardiorespiratory control and bispectral index. Anesthesiology. 2001;94:982-991.
37. Nieuwenhuijs DJF, Olofsen E, Romberg RR, et al. Response surface modeling of remifentanil-propofol interaction on cardiorespiratory control and bispectral index. Anesthesiology. 2003;98:312-322.
38. Maitre PO, Bührer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression: application to midazolam. J Pharmacokinet Biopharm. 1991;19:377-384.
39. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokineticpharmacodynamic models. J Pharmacokinet Biopharm. 1992;20:511-528.
40. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
41. Olofsen E, Dahan A. Response surface modeling of drug interactions: model selection and multimodel inference using the bootstrap. In: Ward DS, Dahan A, Teppema LJSM, eds. Pharmacology and Pathophysiology of the Control of Breathing. New York: Marcel Dekker; 2005.
42. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effects models. Pharm Res. 1999;16:709-717.
43. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn. 2004;31:109-134.
44. Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
45. Wallenstein GC, Stangier J, Ludden TM. Analyzing rich data using different methods provided by NONMEM: pharmacokinetics of telmisartan following intravenous infusion to healthy volunteers. Pharm Res. 1999;16:772-776.
46. Jonsson EN, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci. 2000;2:E32.
47. Lindsey JK, Jones B, Jarvis P. Some statistical issues in modelling pharmacokinetic data. Stat Med. 2001;20:2775-2783.
48. Sheiner LB. The intellectual health of clinical drug evaluation. Clin Pharmacol Ther. 1991;50:4-9.
49. Burnham KP, Anderson DR. Model Selection and Multimodel Inference, 2nd ed. New York: Springer; 2002.
50. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
51. Kuipers JA, Boer F, DeRoode A, Olofsen E, Bovill JG, Burm AGL. Modeling population pharmacokinetics of lidocaine: should cardiac output be included as a patient factor? Anesthesiology. 2001;94:566-573.
52. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997;86:24-33.
53. Short TG, Ho TY, Minto CF, Schnider TW, Shafer SL. Efficient trial design for eliciting a pharmacokinetic-pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drugs. Anesthesiology. 2002;96:400-408.
54. Roy A, Ette EI. A pragmatic approach to the design of population pharmacokinetic studies. AAPSJ PharmSciTech. In press.
55. Lu W, Bailey JM. Reliability of pharmacodynamic analysis by logistic regression - a simulation study. Anesthesiology. 2000;92:985-992.
56. Jönsson S, Kjellson MC, Karlsson MO. Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn. 2004;31:299-320.
57. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171-192.
58. Maitre PO, Stanski DR. Bayesian forecasting improves the prediction of intraoperative plasma concentrations of alfentanil. Anesthesiology. 1988;69:652-659.
59. Brater DC. Bayesian dosing of anesthetic agents: esoteric or practical. Anesthesiology. 1988;69:641-462.
60. Schnider TW, Minto CF, Bruckett H, Mandema JW. Population pharmacodynamic modeling and covariate detection for central neural blockade. Anesthesiology. 1996;85:502-512.
61. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294-305.
62. Gentilini A, Frei CW, Glattfedler AH, et al. Multitasked closed-loop control in anesthesia. IEEE Eng Med Biol Mag. 2001;20:39-53.
63. Fisher DM, Wright PMC. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants? Anesthesiology. 1997;86:567-575.